We therefore chose CCX872 to test the hypothesis that specific inhibition of CCR2 would result in decreased proteinuria and improved renal function in both the Adriamycin model and the 5/6 nephrectomy model of FSGS. This evidence concerns the gene CCR2 and focal segmental glomerulosclerosis.